

PG4894USW

1615
JFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Weingarten et al.

Serial No.: 10/524,462

Group Art Unit: 1615

File Date: October 18, 2005

Examiner:

For: Pyrimidine Derivatives As Selective COX-2 Inhibitors

Director of the U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed: References 10-26
☐ Copies of the references were submitted in parent application _____ (37 CFR 1.98(d))
☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

- B. ☐ The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
- (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311, whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.


☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).

☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



J. Scott Young
Registration No. 45,582

Date: 14 Nov 2005
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8160
Facsimile: (919) 483-7988

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.
PG4894USW

SERIAL NO.
10/524,462

APPLICANT: Weingarten et al.

FILING DATE:
10/18/05

GROUP
1615

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1	3,149,109	Sept. 15, 1964	Neustaedter et al.			
	2	5,474,995	Dec. 12, 1995	Ducharme et al.			
	3	5,760,068	June 2, 1998	Talley et al.			
	4	5,972,986	Oct. 26, 1999	Seibert et al.			
	5	6,020,343	Feb. 1, 2000	Belley et al.			
	6	6,153,619	Nov. 28, 2000	Wood et al.			
	7	6,306,866	Oct. 23, 2001	Wood et al.			
	8	6,313,072	Nov. 6, 2001	Scheiblich et al.			
	9	2003/0013717	Jan. 16, 2003	Mangel et al.			

Continue on page

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	10	DE 19909541	Mar. 4, 1999	GERMANY			Abstract only
	11	JP 9241161	Sept. 16, 1997	JAPAN			Abstract only
	12	WO 96 24585	Aug. 15, 1996	WIPO			
	13	WO 96 41625	Dec. 27, 1996	WIPO			
	14	WO 96 41645	Dec. 27, 1996	WIPO			
	15	WO 9607641	Mar. 14, 1996	WIPO			Abstract only
	16	WO 98 16227	Apr. 23, 1998	WIPO			
	17	WO 98/24782	June 11, 1998	WIPO			
	18	WO 99 01439	Jan. 14, 1999	WIPO			
	19	WO 02/096427	Dec. 5, 2002	WIPO			
	20	WO 02/096885	Dec. 5, 2002	WIPO			

Continue on page

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

	21	Damasio, A.R., et al. Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, Vol. 2, pp. 1992-1996, 1996.
	22	Douglas, R.G., Jr. "Introduction to Viral Diseases: Cecil Textbook of Medicine, 20 th Edition, Vol. 2, pp. 1739-1747, 1996.
	23	Freston, J.W., et al. Rationalizing Cyclooxygenase (COX) Inhibition for Maximal Efficacy and Minimal Adverse Events + Abstract, Am. J. Med. 107(6A):78S-88S; Discussion 89S, December 1999.
	24	Layzer, R.B., et al. Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20 th Edition, Vol. 2, pp. 2050-2057, 1996.
	25	Naesdal, J. et al. "Gastro-Duodenal Protection in an Era of Cyclo-Oxygenase-2-Selective Nonsteroidal Anti-inflammatory Drugs." PubMed Abstract, Eur J Gastroenterol Hepatol, 13(12):1401-1406, December 2001.
	26	Simone, JV., et al. "Oncology: Introduction, Cecil Textbook of Medicine, 20 th Edition, Vol. 1, pp. 1004-10, 1996.

Continue on page

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Applicant(s): Weingarten et al.

Docket No.

PG4894USW

Application No.

10/524,462

Filing Date

October 18, 2005

Examiner

Customer No.

23347

Group Art Unit

1615

Invention: Pyrimidine Derivatives As Selective GPCR Inhibitors

I hereby certify that this Supplemental IDS w/references

(Identify type of correspondence)

is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope

addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

Nov. 18, 2005

(Date)

Valerie L. Phillips

(Typed or Printed Name of Person Mailing Correspondence)

Valerie L. Phillips

(Signature of Person Mailing Correspondence)